The spectrum of medical therapies to treat COVID-19 continues to evolve and address SARS-CoV-2 variants. Sotrovimab no longer included in the Washington State allocation/distribution. Bebtelovimab is the alternate mAb for treatment and is readily available for allocation from the Washington State Department of Health. The DOH also no longer recommends the use of a tiered system to determine eligibility for EVUSHELD. For questions related to therapeutics, please reach out to the Washington State Department of Health Medical Countermeasure Team at mcm@doh.wa.gov. Please review the resources below for additional information:
- Interim DOH Guidance on Use of EVUSHELD for COVID-19 (Updated 3/30/2022)
- ASPR Weekly Update: Distribution & Administration of COVID-19 Therapeutics (3/30/2022)
- COVID-19 Therapeutics Infographic (DOH March 2022)
- Pre-Exposure Prophylaxis Infographic (DOH March 2022)
- Oral Antivirals Face Sheet (DOH March 2022)
- Bird’s Eye Medical EVUSHELD Flyer
